[1] Loomba R, Adams L A. The 20% rule of NASH progression: the natural history of advanced fibrosis and cirrhosis caused by NASH[J]. Hepatology,2019,70:1885-1888.
[2] Younossi Z M. Non-alcoholic fatty liver disease-a global public health perspective[J]. Hepatology,2019,70:531-544.
[3] Estes C, Anstee Q M, Arias-Loste M T, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016－2030[J]. Hepatology,2018,69:896-904.
[4] Watanabe M, Tozzi R, Risi R, et al. Beneficial effects of the ketogenic diet on nonalcoholic fatty liver disease: a comprehensive review of the literature[J]. Obes Rev,2020,21(8): 13-24.
[5] European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease[J]. Diabetologia,2016,59(6):1121-1140.
[6] Gepner Y, Shelef I, Schwarzfuchs D, et al. Effect of distinct lifestyle interventions on mobilization of fat storage pools: CENTRAL magnetic resonance imaging randomized controlled trial[J]. Circulation,2018,137(11):1143-1157.
[7] Meir A Y, Rinott E,Tsaban G,et al. Effect of green- Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial[J]. Gut,2021,70(11):2085-2095.
[8] Properzi C, O'Sullivan T A, Sherriff J L, et al. Ad libitum mediterranean and low-Fat diets both significantly reduce hepatic steatosis: a randomized controlled trial[J]. Hepatology,2018,68(5):1741-1754.
[9] Shang F, Li X, Jiang X. Coffee consumption and risk of the metabolic syndrome: a meta-analysis[J]. Diabetes Metab,2016,42(2):80-87.
[10] Abdelmalek M F, Suzuki A, Guy C, et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease[J]. Hepatology,2010,51:1961-1971.
[11] Koopman K E, Caan M W, Nederveen A J, et al. Hypercaloric diets with increased meal frequency, but not meal size, increase intrahepatic triglycerides: a randomized controlled trial[J]. Hepatology,2014,60:545-553.
[12] Babu A F, Csader S, Lok J, et al. Positive effects of exercise intervention without weight loss and dietary changes in NAFLD-related clinical parameters: a systematic review and meta-analysis[J]. Nutrients,2021,13(9):31-35.
[13] Zhang H J, He J, Pan L L, et al. Effects of moderate and vigorous exercise on nonalcoholic fatty liver disease: a randomized clinical trial[J]. JAMA Intern Med,2016,176(8):1074-1082.
[14] Hashida R, Kawaguchi T, Bekki M, et al. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review[J]. Hepatol,2017,66:142-152.
[15] Hatami M, Eftekhari E. The effect of combined aerobic and resistance training on hepatic enzymes in males with nonalcoholic fatty liver[J]. Biotechnol,2016,3:25-29.
[16] Wei H, Qu H, Wang H, et al. Associations between sitting time and non-alcoholic fatty liver diseases in Chinese male workers: a cross-sectional study[J]. BMJ Open,2016,6:e011939.
[17] Seo Y, Sung G H, Lee S, et al. Weekend catch-up sleep is associated with the alleviation of non-alcoholic fatty liver disease[J]. Annals of Hepatology,2022,27:1006-1009.
[18] Liu X, Baecker A, Wu M, et al. Interaction between tobacco smoking and hepatitis B virus infection on the risk of liver cancer in a Chinese population[J]. Cancer,2018,142:1560-1567.
[19] Charatcharoenwitthaya P, Karaketklang K, Aekplakorn W. Cigarette smoking increased risk of overall mortality in patients with non-alcoholic fatty liver disease: a nationwide population-based cohort study[J]. Front Med,2020,7:49-60.
[20] Blomdahl J, Nasr P, Ekstedt M, et al. Moderate alcohol consumption is associated with advanced fibrosis in non-alcoholic fatty liver disease and shows a synergistic effect with type 2 diabetes mellitus[J]. Metabolism Clinical and Experimental, 2021,115:154439.
[21] Pan C S, Stanley T L. Effect of weight loss medications on hepatic steatosis and steatohepatitis: a systematic review[J]. Front Endocrinol (Lausanne),2020,21,11:68-70.
[22] Petroni M L, Brodosi L, Bugianesi E, et al. Management of non-alcoholic fatty liver disease[J]. BMJ,2021,372:48-47.
[23] Sanyal A J, Chalasani N, Kowdley K V, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis[J]. NEJM,2010,362(18):1675-1685.
[24] Nadinskaia M, Maevskaya M, Ivashkin V, et al. Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease[J]. World J Gastroenterol,2021,27(10):959-975.
[25] Eslamparast T, Poustchi H, Zamani F, et al. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study[J]. Am J Clin Nutr,2014,99(3):535-542.
[26] Wong V W, Wong G L, Chan R S, et al. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease[J]. Hepatol,2018,69(6):1349-1356.
[27] Lassailly G, Caiazzo R, Ntandja-Wandji L-C, et al. Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis[J]. Gastroenterology,2020,159(4):1290-1301.
[28] Gasoyan H, Tajeu G, Halpern M T, et al. Reasons for underutilization of bariatric surgery: The role of insurance benefit design[J]. Surg Obes Relat Dis,2019,15(1):146-151.
[29] Brunaldi V O, Neto M G. Endoscopic procedures for weight loss[J]. Curr Obes Rep,2021 ,10(3):290-300.
[30] Chandan S, Mohan B P, Khan S R, et al. Efficacy and safety of intragastric balloon (IGB) in non-alcoholic fatty liver disease (NAFLD): a Comprehensive review and meta-analysis[J]. Obes Surg,2021,31(3):1271-1279.
[31] Hajifathalian K, Mehta A, Ang B, et al. Improvement in insulin resistance and estimated hepatic steatosis and fibrosis after endoscopic sleeve gastroplasty[J]. Gastrointest Endosc,2021,93(5):1110-1118.
[32] Roehlen N, Laubner K, Bettinger D, et al. Duodenal-jejunal bypass liner (DJBL) improves cardiovascular risk biomarkers and predicted 4-year risk of major cv events in patients with type 2 diabetes and metabolic syndrome[J]. Obes Surg,2020,30(4):1200-1210.
[33] de Jonge C, Fuentes S, Zoetendal E G, et al. Metabolic improvement in obese patients after duodenal-jejunal exclusion is associated with intestinal microbiota composition changes[J]. Int J Obes (Lond),2019 ,43(12):2509-2517. |
